Researchers uncover how the skin autonomously produces antibodies through specialized immune structures, maintaining ...

A case series showed that chimeric antigen receptor T-cell therapy targeting CD19 halted the progression of fibrotic organ ...

Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

A research team led by Prof. Wang Haoyi from the Institute of Zoology (IOZ) of the Chinese Academy of Sciences has developed ...

Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.

A news feature on the research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” ...

It sounds a bit like something out of science fiction, but a topical vaccine that is rubbed on the skin is now closer to ...

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...